Pillstats
Tablet, Extended Release

Guaifenesin And Pseudoephedrine Hcl

Guaifenesin + Pseudoephedrine Hydrochloride

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCR05CA03
RxCUI (US)5032
US makers2 labelers
Packages7
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.121$0.243$0.364$0.486Feb 2026May 2026Jul 2026
$0.422
Latest avg · Jul 22, 2026
+1%
Since Feb 18, 2026
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

n/a51015202025 Q12025 Q22025 Q32025 Q42026 Q1
13
Rx · 2026 Q1
258
Units dispensed
4
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Dr.Reddy's laboratories Limitedunknown5SUPPLYING
Aurobindo Pharma Limitedunknown2SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.